作为一个治疗目标,YAP可以逆转对特鲁祖马布的抗药性
Ah-Rong Nam1, Kyoung-Seok Oh1, Ju-Hee Bang1
1Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Korea.
概括
准ROR2-Yes相关蛋白 (YAP) /TEAD通路可以克服HER2-阳性癌症中特鲁苏马布耐药性. 这种方法通过调节PD-L1并促进T细胞激活,恢复了对trastuzumab的敏感性并增强了抗瘤免疫力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 特拉斯图祖马布耐药性是治疗HER2阳性癌症的一个主要障碍.
- 对 Yes 相关蛋白 (YAP) 途径在特拉斯图祖马布耐药性中的作用尚不清楚.
- 对于克服特鲁祖马布耐药性的治疗选择有限.
研究的目的:
- 调查YAP途径在逆苏祖马布耐药性中的作用.
- 评估YAP向作为一种策略,以克服在HER2阳性癌症中对trastuzumab的耐药性.
- 评估YAP抑制对抗瘤免疫力的影响.
主要方法:
- 来自 HER2 阳性胃癌和胆道癌的已确立的抗 trastuzumab (HR) 细胞系.
- 通过分子和细胞测试评估了YAP通路的激活.
- 评估了YAP针对体外和体外异种移植模型的抗瘤作用.
- 通过共同培养实验和流细胞测量,研究了YAP的免疫调节.
主要成果:
- 在HR细胞中观察到YAP/TAZ通路的升级和激活,包括高ROR2和核YAP.
- 取决于YAP/TEAD的Wnt5a表达式创建了一个积极反循环,放大YAP活动.
- 向YAP恢复了对trastuzumab的敏感性,增加了CD4+和CD8+T细胞激活,并减少了PD-L1的表达.
- 在HR瘤模型中,YAP-TEAD抑制剂维特波芬降低了瘤生长和增加了亡.
结论:
- 准ROR2-YAP/TEAD轴是一个有前途的战略,以克服特鲁祖马布耐药性.
- 这种方法可以提高治疗效率,并改善HER2阳性癌症的临床结果.
- 抑制YAP调节瘤免疫微环境,这表明组合疗法的潜力.
关键词:
在HER2中,HER2是HER2.河马信号通道的信号通道后祖马布耐药性 后祖马布耐药性在 Verteporfin 中使用.哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈更多相关视频
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.2K
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
7.9K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
